コンテンツへスキップ
Merck
  • Near-infrared fluorescent ribonuclease-A-encapsulated gold nanoclusters: preparation, characterization, cancer targeting and imaging.

Near-infrared fluorescent ribonuclease-A-encapsulated gold nanoclusters: preparation, characterization, cancer targeting and imaging.

Nanoscale (2012-12-20)
Yifei Kong, Jun Chen, Feng Gao, Rik Brydson, Benjamin Johnson, George Heath, Yue Zhang, Lin Wu, Dejian Zhou
要旨

Ultra-small gold nanoclusters (AuNCs) have unique size-dependent optical, electrical and chemical properties. They have emerged as a new nanomaterial with broad applications in optoelectronics, catalysis, biosensing, and bioimaging. Several strategies have been exploited to prepare AuNCs of different "magic number" sizes, using different templates e.g. dendrimers, polyethyleneimines, peptides, and more recently, proteins. Notwithstanding, almost all bio-template-protected AuNCs reported so far exhibit fairly low fluorescence quantum yields (QYs), typically <5%, which is especially true for AuNCs prepared using the protein templates. In this paper, we report a facile, one-pot aqueous synthesis of highly fluorescent AuNCs using bovine pancreatic ribonuclease A (RNase-A) as the bio-template. The as-prepared AuNCs not only fluoresce strongly at the near-infrared (NIR) region (λ(em) = 682 nm), but also exhibit an elevated QY of ∼12%. Additionally, the RNase-A-encapsulated AuNC (RNase-A-AuNC) displays an exceptionally large Stokes shift of ∼210 nm as well as a single dominant fluorescence lifetime of ∼1.5 μs, about three orders of magnitude longer than biological autofluorescence. Furthermore, by coupling vitamin B(12) (VB(12)) to the RNase-A-AuNC, we develop a multifunctional nanoplatform that is suitable for simultaneous targeting and imaging of cancer at the cellular level using Caco-2 cell lines as an in vitro model. Since VB(12) has effective uptake pathways in the digestive system, this nanoplatform may have potential for targeted oral drug delivery in vivo.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
リボヌクレアーゼA ウシ膵臓由来, Type I-A, powder, ≥60% RNase A basis (SDS-PAGE), ≥50 Kunitz units/mg protein
Sigma-Aldrich
リボヌクレアーゼA ウシ膵臓由来, for molecular biology, ≥70 Kunitz units/mg protein, lyophilized
Sigma-Aldrich
リボヌクレアーゼA ウシ膵臓由来, Type III-A, ≥85% RNase A basis (SDS-PAGE), 85-140 Kunitz units/mg protein
Sigma-Aldrich
リボヌクレアーゼA ウシ膵臓由来, (Solution of 50% glycerol, 10mM Tris-HCL pH 8.0)
Sigma-Aldrich
リボヌクレアーゼA ウシ膵臓由来, Type I-AS, 50-100 Kunitz units/mg protein
Sigma-Aldrich
リボヌクレアーゼA ウシ膵臓由来, Type XII-A, ≥90% (SDS-PAGE), 75-125 Kunitz units/mg protein
Sigma-Aldrich
リボヌクレアーゼA ウシ膵臓由来, Type II-A, ≥60% (SDS-PAGE), >= 60 Kunitz units/mg protein
Sigma-Aldrich
リボヌクレアーゼB ウシ膵臓由来, BioReagent, ≥50 Kunitz units/mg protein, ≥80% (SDS-PAGE)
Sigma-Aldrich
リボヌクレアーゼA ウシ膵臓由来, Type X-A, ≥90% (SDS-PAGE), ≥70 Kunitz units/mg protein